CytoSeek’s uses cell membrane augmentation technology to unlock the potential of next generation of advanced therapies.

They are a spinout company from the University of Bristol. The novel cell membrane augmentation technology enables them to add new functionalities to cell therapies including tissue-specific targeting and enhanced cell survivability.

CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. They would like to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.


Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


Associated Team Members

Relevant News

Spin out secures £1.1M for ground-breaking ‘supercharged’ cell therapies to treat solid tumours

25 November 2019 A University of Bristol spin-out company has raised £1.1 million in funding…

read more

CytoSeek Wins at Launch: Great West Rising Star Award

© Giulia Spadafora / Soul Media UKI2S would like to congratulate CytoSeek on winning the…

read more

More Companies in Medical / Biotechnology